0 items
Your cart is empty.
Elivena supplies Secretagogues as research-grade compounds intended exclusively for qualified researchers, laboratories, and scientific institutions. This category replaces the previous Muscle Growth & Performance Peptides category with terminology that more accurately reflects laboratory research applications and avoids human-use implications.
Secretagogues include peptide compounds studied in secretion-related pathway models, receptor activation assays, endocrine signalling research, pituitary-associated systems, growth-factor-related molecular mechanisms, and intracellular messenger cascade analysis.
Synergistic GHRH/GH secretagogue blend for enhanced GH release and body composition. Dual vial.
Short-acting GHRH analogue stimulating pulsatile growth hormone release. Research-grade, 10mg vial.
Long-acting GHRH analogue with Drug Affinity Complex for extended growth hormone release. 5mg vial.
Long-acting GHRH analogue with Drug Affinity Complex for extended growth hormone release. 10mg vial.
Long-acting GHRH analogue with Drug Affinity Complex for extended growth hormone release. 5mg vial.
Synergistic GHRH and GH secretagogue blend for amplified pulsatile growth hormone release.
Myostatin inhibitor protein supporting muscle growth and regulating reproductive function. 1mg vial.
Growth hormone releasing peptide-2 stimulating GH and IGF-1 for recovery and growth. 5mg vial.
Growth hormone releasing peptide-2 stimulating GH and IGF-1 for recovery and growth. 10mg vial.
Growth hormone releasing peptide-6 increasing GH secretion and appetite stimulation. 5mg vial.
Growth hormone releasing peptide-6 increasing GH secretion and appetite stimulation. 10mg vial.
We work with leading pharmaceutical brands specializing in Secretagogues medications, selected for their clinical reliability, regulatory compliance, and consistent treatment outcomes.
Secretagogues are classified as compounds studied for their interaction with secretion-regulating pathways in controlled experimental systems. In peptide research, this may include compounds investigated for receptor-mediated signalling, endocrine cell response models, pituitary-associated molecular activity, and growth-factor-related pathways.
Research involving Secretagogues may focus on receptor activation, intracellular second messenger systems, gene expression changes, and pathway-level responses in defined laboratory models.
Classification is based only on molecular research relevance and does not imply physiological or clinical activity.
Secretagogues may be studied in receptor-binding models and ligand-response assays. Experimental endpoints may include:
These assays are used to study molecular interactions in vitro and do not describe human endocrine outcomes.
Some Secretagogues may appear in research involving pituitary-associated or endocrine cell systems. Areas of investigation may include:
These models support controlled scientific investigation only.
Certain compounds may be studied in ghrelin receptor systems or growth-factor-associated pathway models. Research endpoints may include:
All applications are restricted to laboratory research.
Researchers selecting Secretagogues typically assess:
Elivena provides product specifications where available, including molecular weight, purity, storage requirements, and handling information.
Elivena does not provide experimental design guidance, dosing recommendations, or interpretation of research outcomes.
Secretagogues are supplied as research-use-only biochemical compounds. Documentation may include:
Elivena does not supply Secretagogues for human or veterinary administration.
Ipamorelin 5 mg is a peptide used to stimulate the hypothalamus and increase growth hormone levels
Growth hormone releasing peptide-2 stimulating GH and IGF-1 for recovery and growth. 5mg vial.
MGF IGF-1Ec 5mg is used to aid in muscle recovery and peptide performance concerns
Growth hormone releasing peptide-6 increasing GH secretion and appetite stimulation. 10mg vial.
Research-grade synthetic growth hormone-releasing hormone analog formulated in 5mg quantity for GHRH peptide studies and pituitary hormone research in controlled laboratory environments.
Short-acting GHRH analogue stimulating pulsatile growth hormone release. Research-grade, 10mg vial.
